Excelsus invites pharma companies to explore for free the possibilities of synchrotron X-ray powder diffraction

Let Excelsus' team of experienced synchrotron scientists help you with your compound characterization.
Let Excelsus' team of experienced synchrotron scientists help you with your compound characterization.

Did you like this article? Please share it.



The second annual Spring Pharmaceutical Synchrotron X-Ray Powder Diffraction (SPS-XRPD-2) Workshop, organized together with the 16th Pharmaceutical Powder X-ray Diffraction Symposium (PPXRD-16) by the International Centre for Diffraction Data (ICDD) and Excelsus Structural Solutions (ESS), will take place at the Paul Scherrer Institute (PSI) May 9-12, 2019. In support of the conference, Excelsus in cooperation with the Swiss Light Source (SLS) Materials Science beam line is launching a complimentary case study program, allowing the pharmaceutical industry to explore the possibilities offered by synchrotron x-ray powder diffraction, free of charge.

Since 2012, Excelsus Structural Solutions, a spin-off of the Paul Scherrer Institute (PSI), has been offering easy, affordable access to innovative synchrotron characterization techniques tailored to fit the needs of the pharmaceutical industry. Examples of S-XRPD applications include purity assessments of active pharmaceutical ingredients (APIs) or formulations, structure determination, trace analyses, quantitative phase analysis and amorphous quantification. Among the company’s clients are industry leaders such as Novartis, Cilag, Janssen Pharmaceutica, BASF, and others.

This fall, Excelsus is offering pharmaceutical companies facing challenges in compound characterization a unique opportunity to test synchrotron X-ray powder diffraction (S-XRPD) at no cost. Synchrotron-generated X-rays are at least five orders of magnitude more intense than the best laboratory X-ray source. S-XRPD thus offers improved angular resolution, counting statistics, energy tunability, and fast acquisition time (milliseconds to a few minutes). This makes it possible to reach levels of detection as small as 0.01% – particularly useful for highly potent drugs and micro dosage formulations.

To participate in the program, the company should release non-proprietary drug material for the S-XRPD analysis that exhibits specific problems or raises particular questions. The results will be presented during the joint PPXRD-16/SPS-XRPD-2 workshop. Companies willing to seize this unique opportunity to discover the innovative analytical method are asked to apply by February 28, 2019, submitting a short proposal explaining their case.